blood lymphocytes as effectors, CD81 cytotoxic T lymphocytes against HGP-30-coated targets were identified in seropositive individuals. In this report we demonstrate that a synthetic p17 epitope can be a target for major histocompatibility complexrestricted cytotoxic T lymphocytes in HIV-infected individuals.
Several approaches to the development of an AIDS vaccine are currently being explored, but to date a consensus of what is the appropriate protective response required for protection has not developed (1) . An important part of such studies is the characterization of the host immune response, both humoral and cell-mediated, to human immunodeficiency virus type 1 (HIV-1). Defining the immune response is important since disease stabilization can be contrasted with disease progression and immunodominant epitopes for a large number of individuals can be defined (2) (3) (4) . § With respect to the cell-mediated immune protection, cytotoxic T lymphocytes (CTLs) may be extremely important in the host defense mechanism against this infection since HIV transmission is often cell-associated, and the viral particles in that instance may not be easily accessible to neutralizing antibodies. CTL responses specific for the major viral proteins, env, gag, and pol, have been reported, and to date all could be of potential significance for protection since no correlation between CTLs against specific epitopes has been demonstrated (6) (7) (8) (9) (10) .
Early studies have shown that a 30-amino acid synthetic HIV-1 gag p17-related peptide (HGP-30) is immunogenic in a variety of species and contains both T-cell and B-cell epitopes and that antibodies directed against the HIV-1 p17 epitope neutralize HIV-1 in culture (11) (12) (13) (14) (15) (16) . ¶ The antibodies directed against HGP-30 cross-react with HIV p17 as defined by Western blot (12) . Also, monoclonal antibodies to HIV p17 bind to the surface of HIV-infected cells. 1 1 These studies are confirmed by reports of HIV p17 on the cell surface of infected cells by using monoclonal antibodies (mAbs) whose epitope recognition has not been defined (18) . In this report, cells from HIV-1-infected individuals were examined for the presence of CTLs specific for the HGP-30 epitope of HIV-1 p17.
MATERIALS AND METHODS
Antibodies. mAbs to human lymphocyte surface markers CD4 (OKT4) and CD8 (OKT8) were obtained from Ortho Diagnostics.
HLA Typing. HLA transplantation antigens were identified serologically at the tissue-typing laboratories of Hospital Saint-Louis (Paris) and Centre National de Transfusion Sanguine.
Lymphocyte Donors. Healthy HIV-seronegative controls were volunteers who received an HIV envelope vaccine (subjects 1 and 2) (19) or HGP-30 core vaccine (subject AG) and an HIV-negative individual (subject 3) who was a donor from the Centre National de Transfusion Sanguine blood bank. Subjects 4-7 were asymptomatic HIV carriers; subjects 8 and 9 had AIDS-related complex.
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PBL from donors by mixing 1 x 106 PBL with 2 x 105 x-ray-irradiated (10,000 rad; 1 rad = 0.01 Gy) HIV-1-infected autologous phytohemagglutinin-stimulated blasts (15-30% of them expressed cell surface HIV-1 antigens as detected by immunofluorescence). Cultures were established in 24-well culture plates (Falcon, Becton Dickinson) in 2 ml of RPMI supplemented with 1 mM sodium pyruvate, 2 mM L-glutamine, penicillin at 100 units/ml, streptomycin at 100 tig/ml, and 10% fetal calf serum.
HGP-30 Peptide. The synthetic p17 peptide termed HGP-30 was provided by Viral Technologies (Washington, DC). This analogue is identical to the HIV-1 (ARV) p17 amino acid sequence from residue 88 to 115 (12) . The peptide length was determined by the requirement that it contain the naturally occurring tyrosine in the viral protein sequence for subsequent labeling studies, that it be small enough for rapid and efficient synthesis, and that it be symmetrical around the region of homology with thymosin a1, where neutralizing antibodies were directed in initial studies (11) .
Transfected Mouse Tumor Cells. P815 mouse tumor cells and P815 cells transfected with HLA-A2, P815-A2 cells (20) , were grown in Dulbecco's minimal essential medium supplemented with 10% fetal calf serum.
Cytotoxicity Assay. Lymphocyte suspensions were tested for cytotoxicity after a 6-day culture in autologous MLC with a standard 6-hr 5tCr release assay (21) . One hour after contact with peptide HGP-30 at a final concentration of 10 ,ug/ml (=31 ,uM), 4 x 106 EBV-transformed B cells were resuspended with 200 ,uCi of Na25tCrO4 (1 Ci = 37 GBq) for 90 min at 37°C, washed extensively, and used as targets. Percent specific cytotoxicity was determined from the formula: 100 x (release in assay -spontaneous release)/(maximum release -spontaneous release). Maximum release was determined by lysis with 1 M HCI. Average spontaneous chromium release for all assays was 20% of the maximum.
RESULTS
Cytotoxic T-Cell Responses in HIV-Seropositive Individuals. Evaluation of cytotoxic T cells in seropositive individuals to gag epitopes is generally difficult unless populations are expanded prior to utilization and autologous (histocompatible) targets are used. B lymphoblastoid cells were used as targets in an autologous chromium release assay, where lysis of labeled target cells results in release of chromium into the culture medium as an indirect measure of cytotoxicity. Immortalized B-cell lines were established from six HIV-1-seropositive and three seronegative controls, pulsed with HGP-30, and used as CTL targets. HIV-specific CTLs were generated in autologous MLC with irradiated HIV-1-infected autologous phytohemagglutinin-stimulated blasts and used as effector cells in the assay. The results for each subject grouped by clinical and serological status are presented in Fig. 1 at a representative effector-to-target ratio of 30:1. (22) .
In each of the seropositive subjects ( Fig. 1 B and C) , the HGP-30-specific cytotoxic response was 3-to 16-fold higher than that observed for the control target cells. Similarly, low background cytotoxicity of the EBV-transformed control cells were found in all cases except one of the seropositive subjects (Fig. 1C, subject 9 ). The reason for higher cytotox- icity of the control cells in this HIV-seropositive patient (subject 9) is not known.
Western Blot Analysis. Western blot analysis of the sera analyzed (subjects [4] [5] [6] [7] [8] showed concordance between humoral and cellular responses, since CTL activity was seen in all individuals with detectable antibodies to p17 (Fig. 2) .
Identification of the Cells as CD8. The cell type responsible for the observed cytotoxicity was identified by way of mAbs directed against CD8. Addition of the CD8-specific mAb inhibited the HGP-30-specific cytotoxicity in all three seropositive subjects (Fig. 3) . In the three HIV-seropositive subjects, lysis of autologous HGP-30-pulsed target cells was 80%, 65%, and 30% above values for B-lymphoblastoid control target cells. Lysis in the presence of saturating concentrations ofthe mAb against CD8 was 12%, 15%, and 10%, respectively. Thus, the cytotoxicity appears to be mediated by a CD8+ T lymphocyte, the predominant phenotype that mediates CTL activity in most other viral systems (21). HIV-specific human CTLs were generated in autologous MLC with PBLs from the seronegative or seropositive subjects as follows. Autologous phytohemagglutinin-stimulated blasts (2 x 105) were incubated with live HIV, irradiated with x-rays (10,000 rad), and mixed with 1 x 106 PBLs from the subjects. Cultures were used 6 days after initiation. Spontaneous 51Cr release by targets in medium alone varied between 15% and 20%o of the cpm released by 1 
Conformation of the Histocompatibility Requirement of the
Response. The ability of effector cells from seropositive subjects to kill HLA class I nonidentical target cells pulsed with HGP-30 was investigated with cells from three HIV-1 seropositive subjects. As shown in Fig. 4 , lysis of autologous HGP-30-pulsed target cells was 40%o, 38%, and 35%. In these studies, lysis ofthe allogeneic HGP-30-pulsed target cells was significantly lower-18%, 22%, and 15%. The fact that effector cells from three of the subjects tested caused preferential killing of the HGP-30-pulsed autologous target cells (compared to heterologous targets) indicates that the major histocompatibility complex (MHC) may be important in the cytotoxic response against the HIV-1 p17 peptide HGP-30. GP160 I * * Fig. 1 was analyzed by Western blot (DuPont) for antibody to the HIV-1 p17 antigen. Numbers correspond to subjects 4-8. To verify that HLA-A2 can be a restricting determinant for CTL to the HGP-30 peptide, we used the P815 mouse cell line, which is HLA-A and -B negative and its HLA-A2-transfected cell analogue, P815-A2, which is HLA-A2 positive. PBLs from subject 7, after stimulation with HIV antigens, were retested on the p815 and p815-A2 cell lines pulsed with or without the HGP-30 peptide. As shown in Table 2 , P815-A2 cells, but not P815 cells, preincubated with HGP-30 were lysed by effector cells from the HLA-A2 subject 7.
DISCUSSION
To our knowledge, these results are the first to demonstrate that an epitope on the synthetic HIV-1 p17 peptide HGP-30 can be a target for MHC-restricted CD8+ cytotoxic T lymphocytes in HIV-infected individuals. The HIV-specific CTLs recognized the peptide HGP-30 in association with common class I HLA antigens. These studies are consistent with other investigations that have also reported gag-specific CTL responses in cells of some patients (8) (9) (10) .
HIV-1 gag-specific CTLs defined with synthetic peptides have been described (9) , and an epitope in the envelope glycopeptide that is recognized by H-2Dd murine CTLs has also been reported (19) . It is likely that there are several other CTL-specific epitopes in other HIV gene products (6-16, 18, 19, 21, 22) .
Although Plata et 
